Novo Nordisk drops inflammatory disorder business, incurs cost

September 2, 2014 7:41 AM

11 0

Novo Nordisk drops inflammatory disorder business, incurs cost

COPENHAGEN (Reuters) - Danish pharmaceutical company Novo Nordisk said on Tuesday it has decided to stop its activities within inflammatory disorders and only focus on the treatment and prevention of diabetes and obesity.

The decision follows a discontinuation for the company's most advanced drug candidate within the area, a drug used to treat rheumatoid arthritis and known as anti-IL-20, announced on Aug. 7 together with its with second quarter results.

Also read: Pebble Discontinuing Smartwatches After Its Sale to Fitbit

Read more

To category page

Loading...